EBV seroconversion confers markedly increased MS risk in large longitudinal military cohorts, supporting EBV as necessary but ...

Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review. Legal compounding remains ...

Divergent product biology emerged: high-dose responses tracked with naïve/central-memory enrichment, whereas low-dose ...

High-frequency, low-dose rituximab achieved ~85% peripheral CLL clearance within 1 hour and ~34% nodal reduction in 1 week, with macrophage phagocytosis and complement as dominant mechanisms.

The study, “Geographical Access to Preferred Pharmacies in Medicare Part D,” published in the July 2026 issue of The American Journal of Managed Care ® (AJMC ®), analyzed pr ...

Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a ...

Right-sided performance improved most, with adenoma detection rising from 18.0% to 31.8%, addressing a common vulnerability of standard colonoscopy quality and missed proximal lesions.

This segment explores emerging challenges in treatment sequencing for hormone receptor–positive, HER2-negative metastatic breast cancer as oral selective estrogen receptor degraders move into earlier ...

A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries. Richard G. Stearns of the U.S. District Court for the ...

Mean LDL-C at 6 months was 76.3 vs 85.6 mg/dL, yielding an adjusted difference of −6.62 mg/dL and higher attainment of LDL-C <50 mg/dL. Intervention uptake increased intensive and combination ...

Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...

A phase 2, randomized, double-blind trial (N=50) used oral semaglutide 3 mg/day then 7 mg/day, combining cue-reactivity testing with Timeline Follow-Back naturalistic drinking assessment and objective ...